Andra AP fonden Reduces Stock Position in United Therapeutics Corporation $UTHR

Andra AP fonden lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 37.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 73,800 shares of the biotechnology company’s stock after selling 44,600 shares during the quarter. Andra AP fonden owned approximately 0.17% of United Therapeutics worth $30,938,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. grew its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Wilmington Savings Fund Society FSB lifted its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Abich Financial Wealth Management LLC bought a new stake in shares of United Therapeutics during the 3rd quarter valued at $44,000. Finally, Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the completion of the sale, the chief financial officer directly owned 8,142 shares in the company, valued at approximately $3,908,078.58. The trade was a 72.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 407,954 shares of company stock valued at $197,601,528 in the last ninety days. 10.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on UTHR. UBS Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Tuesday, February 17th. TD Cowen boosted their target price on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank Of Canada upped their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday. HC Wainwright increased their price objective on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $533.55.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

United Therapeutics Trading Down 5.9%

UTHR opened at $503.60 on Friday. The firm has a market capitalization of $21.69 billion, a PE ratio of 18.05, a P/E/G ratio of 2.85 and a beta of 0.85. The firm has a 50 day moving average of $484.64 and a two-hundred day moving average of $444.51. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $537.19.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.19 earnings per share. As a group, analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.